When it comes to beginning treatment for rheumatoid arthritis, minutes and seconds may not count, but weeks and months surely do.
In a 3-year study at the University Hospital of Vienna and at Lainz Hospital in Austria, researchers found that there is a definite "window of opportunity" for successful treatment.
The study compared patients with very early disease who had waited an average of 3 months before being started on drugs to a group who had waited 20 months to start therapy.
After just 3 months of treatment, patients with early therapy were doing better than those who had waited longer. At the end of the study, 70% of patients in the early-treatment group showed a 20% improvement in disease symptoms. Meanwhile, only 40% of those in the later-treatment group improved.
The researchers concluded that introducing disease-modifying drugs very early "seems highly beneficial in [rheumatoid arthritis] compared with even relatively short delay."
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs